It goes without saying that artificial intelligence (AI), machine learning (ML), generative AI (GenAI), and large language models (LLMs) are already transforming industry, refining and acce
On International Women’s Day, pharmaphorum looks back to an interview with Miruna Sasu, PhD, CEO of COTA, a real-world data company that is advancing generative AI models for cancer care.
Artificial intelligence (AI) and machine learning are here to stay, so it’s crucial to understand how they can be used to the best effect in the evolving world of clinical trials.<
Eisai has joined forces with Oita University in Japan to develop a machine-learning tool that may be able to predict whether someone is at risk of developing Alzheimer’s d
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin